Impact of mass rapid antigen testing for SARS-CoV-2 to mitigate Omicron outbreaks in China

Zengyang Shao, MSc1,2,†, Lijia Ma, PhD1,†, Yuan Bai, PhD2,3, Qi Tan, PhD3, Xiao Fan Liu, PhD4, Shiyong Liu, PhD5, Sheikh Taslim Ali, PhD2,3, Lin Wang, PhD6, Eric H. Y. Lau, PhD2,3, Benjamin J. Cowling, PhD2,3,* and Zhanwei Du, PhD2,3

1College of Computer Science and Software Engineering, ShenZhen University, Shen Zhen, China, 2Laboratory of Data Discovery for Health Limited, Hong Kong Science Park, Hong Kong, SAR, China, 3WHO Collaborating Center for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, SAR, China, 4Department of Media and Communication, City University of Hong Kong, Hong Kong, SAR, China, 5Institute of Advanced Studies in Humanities and Social Sciences, Beijing Normal University at Zhuhai, Zhuhai, China and 6Department of Genetics, University of Cambridge, Cambridge, UK

*To whom correspondence should be addressed. Email: bcowling@hku.hk
†Zengyang Shao and Lijia Ma contributed equally to this work

Submitted 25 August 2022; Revised 6 September 2022; Editorial Decision 7 September 2022; Accepted 7 September 2022

Key words: Rapid SARS-Cov-2 Antigen Test, Omicron, non-pharmaceutical intervention

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variants have a higher transmissibility and immune escape potential than previous variants, such as Delta variants, leading to their rapid spread around the world. In the mainland of China, >770,000 local cases have been reported from 1 January to 1 July 2022, compared with ~20,000 local cases in 2021.1 In Hong Kong, >120,000 local cases (greater than 15% of the population) have been reported in the same period. From early 2020, the mainland of China and Hong Kong have adopted hybrid non-pharmaceutical interventions (NPIs) (including school closures, workplace closures, public events cancellations and travel bans)4 to contain the recurring outbreaks. Here, we conducted an exploratory analysis of potential correlates of COVID-19 real-time reproduction number ($R_t$) and specific NPIs across four cities in China with large outbreaks of Omicron variants. We investigated these correlates in relation to $R_t$ to disentangle the factors that prevented the spread of Omicron, among the NPIs that policy makers can control.

For the SARS-CoV-2 Omicron variants epidemics in Hong Kong, Shanghai, Changchun and Jilin City in Jilin Province, we collected epidemiology and NPIs data. The epidemiology data include the daily confirmed cases and daily asymptomatic cases (Figure 1). The NPIs data in Oxford COVID-19 Government Response Tracker provide information on Rapid SARS-Cov-2 Antigen Testing (RAT) [such as the date to start using RAT] and 15 other NPIs adopted by Chinese provinces (including School Closures, Workplace Closures, Public Event Cancellations, Gathering Restrictions, Public Transport Closures, Stay-at-Home Restrictions, Urban Travel Restrictions, International Travel Restrictions, Government Income Support, Covid Public Information Testing, Government Testing Policy, Contact Tracing Policy, Mask Policy, Vaccine Policy (such as how vaccines are funded and who to prioritize), Elderly Protection Policy). The study period is from 1 January to 4 May 2022, for Hong Kong, from 1 March to 16 May 2022, for Shanghai, from 4 March to 4 May 2022, for Changchun and from 3 March to 4 May 2022, for Jilin City. Daily $R_t$ in Hong Kong is derived from the real-time dashboard developed by the School of Public Health of The University of Hong Kong,1 and the $R_t$s in Shanghai, Changchun, and Jilin City are calculated using EpiNow2 package6 in R based on the daily confirmed cases (symptomatic with positive Polymerase chain reaction [PCR] result).

The real-time reproduction number $R_t$s in four study cities (Hong Kong, Shanghai, Changchun and Jilin) were tested for associations with RAT indices, asymptomatic case indicators and 18 other demographic, social and political conditions using multiple stepwise regression. For RAT indices, these study cities provide and report RAT results to citizens (0, without RAT; 1 with RAT). For asymptomatic case indicators, since many asymptomatic infected people among Omicron-infected people...
will lead to the spread of the epidemic, identifying asymptomatic infected people is essential for epidemic prevention and control. We use the ratio of the number of asymptomatic cases to the number of confirmed cases to measure the government’s detection capacity. If these modelled associations were to be causal, RAT might have reduced $R_t$ by $0.788$ (95% CI: $-0.306$, $1.880$) in all four cities (Supplementary Figure S1).

We also performed a separate stepwise regression analysis for each city. To further analyse the NPIs closely related to the reduction of $R_t$ in various cities, we compared the results under different model specifications (Supplementary Table S1). We summarized the results using the model with the highest $R^2$ (Supplementary Table S2) and found five NPIs (i.e. RAT, Workplace Closures, Mask Policy, Public Transport Closures and Asymptomatic Case Indicators) are associated with the reduction of $R_t$ in Hong Kong; four NPIs (i.e. RAT, Workplace Closures, Gathering Restrictions and Government Income Support) are associated with the reduction of $R_t$ in Shanghai; four NPIs (i.e. RAT, Workplace Closures, Government Response Index and Asymptomatic Case Indicators) are associated with the reduction of $R_t$ in Changchun; and five NPIs (i.e. RAT, School Closures, Workplace Closures, Government Response Index and Asymptomatic Case Indicators) are associated with the reduction of $R_t$ in Jilin City.

In conclusion, we estimated the effect of NPIs in four cities in China, and RAT is one of the effective NPIs in those cities that has been added as one of the official COVID-19 testing methods since 11 March 2022. RAT can complement the other control measures to reduce transmission. For different cities, RAT in Hong Kong has the most considerable effect and reduces $R_t$ by $1.853$ (95% CI: $1.385$–$2.320$), $0.463$ (95% CI: $0.327$–$0.598$) for Shanghai, $0.469$ (95% CI: $0.071$–$0.867$) for Changchun and $0.434$ (95% CI: $0.075$–$0.793$) for Jilin City. There are two possible explanations. First, RAT is more widely used and
recognized in Hong Kong than in the mainland of China, where PCR is still the ‘gold standard’. Compared with PCR, high-frequency testing programs by RAT offer the potential to break chains of transmission and act as an extra layer of protection in a comprehensive public health response. Second, the manufacturers of the RAT used in Hong Kong and the mainland of China are different. As of July 2022, Hong Kong has approved 20 RAT reagents produced in the United States, France, Hong Kong and the mainland of China (with specificity between 98 and 100% and the sensitivity between 82 and 97.73%), and a total of 31 domestic RAT reagents approved for use in the mainland of China (with the specificity between 93.3 and 100% and the sensitivity between 72 and 100% at $C_T < 25$).

Our study has several limitations. Since Oxford’s data are based on the provincial level, there could be a bias in our assessment of the validity of the NPIs for individual cities. We note that multiple NPI measures are implemented simultaneously, and the potential interactions between those NPIs are not considered. If NPIs in the stepwise regression model are highly correlated, some NPIs may be excluded from the model. However, this has little effect on the analysis of the RAT effect, which is effective in all four study cities.

**Supplementary data**

Supplementary data are available at JTM online

**Data availability**

All data are collected from open source with a detailed description in the Methods section.

**Code availability**

The code used for data analysis is freely available upon request.

**Author contributions**

Z.S., L.M., Z.D., Y.B. and B.J.C.: conceived the study, designed statistical and modelling methods, conducted analyses, interpreted results, wrote and revised the manuscript; Q.T., X.L., S.L., S.T.A., L.W. and E.H.Y.L.: interpreted results and revised the manuscript.

**Funding**

We acknowledge the financial support from the AIR@InnoHK Programme from Innovation and Technology Commission of the Government of the Hong Kong Special Administrative Region, the Health and Medical Research Fund, Food and Health Bureau, Government of the Hong Kong Special Administrative Region (grant no. COVID190118), National Natural Science Foundation of China (grant no. 72104208, 62173236), the Ministry of Education Project Of Humanities and Social Sciences (21YJAZH053), the Natural Science Foundation of Guangdong Province under Grant 2020A1515010790; and in part by the Technology Research Project of Shenzhen City under Grant JCYJ20190808174801673. The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. All code to perform the analyses and generate the figures in this study are available from the corresponding author upon reasonable request.

**Conflict of interest**

B.J.C. reports honoraria from AstraZeneca, Fosun Pharma, GlaxoSmithKline, Moderna, Pfizer, Sanofi Pasteur, and Roche. The authors report no other potential conflicts of interest.

**References**

1. COVID-19 Data Explorer. *Our World in Data* https://ourworldindata.org/coronavirus#coronavirus-country-profiles (accessed 5 July 2022).
2. Du Z, Xu X, Wang L et al. Effects of Proactive social distancing on COVID-19 outbreaks in 58 cities, China. *Emerg Infect Dis* 2020; 26:2267–9.
3. Cai J, Deng X, Yang J et al. Modeling transmission of SARS-CoV-2 Omicron in China. *Nat Med* 2022; 28:1468–75.
4. Hale T, Angrist N, Goldszmidt R et al. A global panel database of pandemic policies (Oxford COVID-19 Government Response Tracker). *Nat Hum Behav* 2021; 5:529–38.
5. Real-time dashboard. *Coronavirus disease 2019* http://covid19.sph.hku.hk/dashboard (accessed 5 May 2022).
6. Abbott S, Hellewell J, Sherratt K, et al EpiNow2: estimate real-time case counts and time-varying epidemiological parameters. https://epiforecasts.io/EpiNow2/ (accessed 10 May 2022).
7. Rosella LC, Agrawal A, Gans J et al. Large-scale implementation of rapid antigen testing system for COVID-19 in workplaces. *Sci Adv* 2022; 8:eabm3608.
8. Du Z, Tian L, Jin DY. Understanding the impact of rapid antigen tests on SARS-CoV-2 transmission in the fifth wave of COVID-19 in Hong Kong in early 2022. *Emerg Microbes Infect* 2022; 11:1–19.
9. Department of health. https://www.mdd.gov.hk/en/whats-new/rapid-antigen-tests-covid-19/index.html (accessed 27 July 2022).
10. Nation Medical Products Administration. https://www.nmpa.gov.cn/yaowen/ypjgyw/20220429161546149.html (accessed 27 July 2022).